Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism
Summary Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19). Methods : Two hundred H. pylori‐infected dyspeptic patients we...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2005-02, Vol.21 (3), p.283-288 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 288 |
|---|---|
| container_issue | 3 |
| container_start_page | 283 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 21 |
| creator | Sheu, B.‐S. Kao, A.‐W. Cheng, H.‐C. Hunag, S.‐F. Chen, T.‐W. Lu, C.‐C. Wu, J.‐J. |
| description | Summary
Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19).
Methods : Two hundred H. pylori‐infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
Results : The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention‐to‐treat analysis: 79% vs. 86%, P > 0.05; per‐protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per‐protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P |
| doi_str_mv | 10.1111/j.1365-2036.2005.02281.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67406949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67406949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5131-59027d6d879efbe16f3e80ac36f11632859915a33b101227b4397317dfb131763</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS1ERYeBV0DewC7BPxMnXrCoRoVWqtQuyoKV5TjX4JETBzujNqyQ4El5kjrMqN3WG1_pfMfXOgchTElJ8_m4KykXVcEIFyUjpCoJYw0t71-g1aPwEq0IE7LIAj9Fr1PaEUJETdgrdEorISknfIX-nqfQwxj1r-ABb8i_33_673i6cwZwp52fsRvwFN2Y1ekHRD3OWA_dMmOw1hltZhwsvgDvTGi1mSDicfYhOpzpLgOTCwOO4PUE2Rfw9tsN21KJe5h0G7xL_Rt0YrVP8PZ4r9HXz-e324vi6vrL5fbsqjAV5bSoJGF1J7qmlmBboMJyaIg2XFhKBWdNJSWtNOctJZSxut1wWXNad7bN9lrwNfpweHeM4ece0qR6lwx4rwcI-6REvSFCbmQGmwNoYkgpglVjdL2Os6JELQ2onVqCVkvQamlA_W9A3Wfru-OOfdtD92Q8Rp6B90dAJ6O9jXowLj1xouLV0tkafTpwd87D_OwPqLOb22XiD6RcoZc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67406949</pqid></control><display><type>article</type><title>Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Sheu, B.‐S. ; Kao, A.‐W. ; Cheng, H.‐C. ; Hunag, S.‐F. ; Chen, T.‐W. ; Lu, C.‐C. ; Wu, J.‐J.</creator><creatorcontrib>Sheu, B.‐S. ; Kao, A.‐W. ; Cheng, H.‐C. ; Hunag, S.‐F. ; Chen, T.‐W. ; Lu, C.‐C. ; Wu, J.‐J.</creatorcontrib><description>Summary
Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19).
Methods : Two hundred H. pylori‐infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
Results : The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention‐to‐treat analysis: 79% vs. 86%, P > 0.05; per‐protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per‐protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P < 0.05).
Conclusion : Esomeprazole 40 mg twice daily for triple therapy may improve the H. pylori eradication compared to omeprazole‐based therapy, but only for homologous extensive metabolizers of CYP2C19.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2005.02281.x</identifier><identifier>PMID: 15691303</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Amoxicillin - administration & dosage ; Amoxicillin - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - therapeutic use ; Aryl Hydrocarbon Hydroxylases - genetics ; Aryl Hydrocarbon Hydroxylases - metabolism ; Biological and medical sciences ; Chi-Square Distribution ; Clarithromycin - administration & dosage ; Clarithromycin - therapeutic use ; Cytochrome P-450 CYP2C19 ; Digestive system ; Drug Administration Schedule ; Drug Therapy, Combination ; Esomeprazole ; Female ; Follow-Up Studies ; Gastric Mucosa - enzymology ; Gastroenterology. Liver. Pancreas. Abdomen ; Genotype ; Helicobacter Infections - drug therapy ; Helicobacter Infections - enzymology ; Helicobacter pylori ; Humans ; Male ; Medical sciences ; Mixed Function Oxygenases - genetics ; Mixed Function Oxygenases - metabolism ; Omeprazole - administration & dosage ; Omeprazole - therapeutic use ; Pharmacology. Drug treatments ; Risk</subject><ispartof>Alimentary pharmacology & therapeutics, 2005-02, Vol.21 (3), p.283-288</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5131-59027d6d879efbe16f3e80ac36f11632859915a33b101227b4397317dfb131763</citedby><cites>FETCH-LOGICAL-c5131-59027d6d879efbe16f3e80ac36f11632859915a33b101227b4397317dfb131763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2005.02281.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2005.02281.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16535281$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15691303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheu, B.‐S.</creatorcontrib><creatorcontrib>Kao, A.‐W.</creatorcontrib><creatorcontrib>Cheng, H.‐C.</creatorcontrib><creatorcontrib>Hunag, S.‐F.</creatorcontrib><creatorcontrib>Chen, T.‐W.</creatorcontrib><creatorcontrib>Lu, C.‐C.</creatorcontrib><creatorcontrib>Wu, J.‐J.</creatorcontrib><title>Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19).
Methods : Two hundred H. pylori‐infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
Results : The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention‐to‐treat analysis: 79% vs. 86%, P > 0.05; per‐protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per‐protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P < 0.05).
Conclusion : Esomeprazole 40 mg twice daily for triple therapy may improve the H. pylori eradication compared to omeprazole‐based therapy, but only for homologous extensive metabolizers of CYP2C19.</description><subject>Adult</subject><subject>Amoxicillin - administration & dosage</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Biological and medical sciences</subject><subject>Chi-Square Distribution</subject><subject>Clarithromycin - administration & dosage</subject><subject>Clarithromycin - therapeutic use</subject><subject>Cytochrome P-450 CYP2C19</subject><subject>Digestive system</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Esomeprazole</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric Mucosa - enzymology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genotype</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - enzymology</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Mixed Function Oxygenases - metabolism</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhS1ERYeBV0DewC7BPxMnXrCoRoVWqtQuyoKV5TjX4JETBzujNqyQ4El5kjrMqN3WG1_pfMfXOgchTElJ8_m4KykXVcEIFyUjpCoJYw0t71-g1aPwEq0IE7LIAj9Fr1PaEUJETdgrdEorISknfIX-nqfQwxj1r-ABb8i_33_673i6cwZwp52fsRvwFN2Y1ekHRD3OWA_dMmOw1hltZhwsvgDvTGi1mSDicfYhOpzpLgOTCwOO4PUE2Rfw9tsN21KJe5h0G7xL_Rt0YrVP8PZ4r9HXz-e324vi6vrL5fbsqjAV5bSoJGF1J7qmlmBboMJyaIg2XFhKBWdNJSWtNOctJZSxut1wWXNad7bN9lrwNfpweHeM4ece0qR6lwx4rwcI-6REvSFCbmQGmwNoYkgpglVjdL2Os6JELQ2onVqCVkvQamlA_W9A3Wfru-OOfdtD92Q8Rp6B90dAJ6O9jXowLj1xouLV0tkafTpwd87D_OwPqLOb22XiD6RcoZc</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Sheu, B.‐S.</creator><creator>Kao, A.‐W.</creator><creator>Cheng, H.‐C.</creator><creator>Hunag, S.‐F.</creator><creator>Chen, T.‐W.</creator><creator>Lu, C.‐C.</creator><creator>Wu, J.‐J.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism</title><author>Sheu, B.‐S. ; Kao, A.‐W. ; Cheng, H.‐C. ; Hunag, S.‐F. ; Chen, T.‐W. ; Lu, C.‐C. ; Wu, J.‐J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5131-59027d6d879efbe16f3e80ac36f11632859915a33b101227b4397317dfb131763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Amoxicillin - administration & dosage</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Biological and medical sciences</topic><topic>Chi-Square Distribution</topic><topic>Clarithromycin - administration & dosage</topic><topic>Clarithromycin - therapeutic use</topic><topic>Cytochrome P-450 CYP2C19</topic><topic>Digestive system</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Esomeprazole</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric Mucosa - enzymology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genotype</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - enzymology</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Mixed Function Oxygenases - metabolism</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheu, B.‐S.</creatorcontrib><creatorcontrib>Kao, A.‐W.</creatorcontrib><creatorcontrib>Cheng, H.‐C.</creatorcontrib><creatorcontrib>Hunag, S.‐F.</creatorcontrib><creatorcontrib>Chen, T.‐W.</creatorcontrib><creatorcontrib>Lu, C.‐C.</creatorcontrib><creatorcontrib>Wu, J.‐J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheu, B.‐S.</au><au>Kao, A.‐W.</au><au>Cheng, H.‐C.</au><au>Hunag, S.‐F.</au><au>Chen, T.‐W.</au><au>Lu, C.‐C.</au><au>Wu, J.‐J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2005-02</date><risdate>2005</risdate><volume>21</volume><issue>3</issue><spage>283</spage><epage>288</epage><pages>283-288</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19).
Methods : Two hundred H. pylori‐infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
Results : The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention‐to‐treat analysis: 79% vs. 86%, P > 0.05; per‐protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per‐protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P < 0.05).
Conclusion : Esomeprazole 40 mg twice daily for triple therapy may improve the H. pylori eradication compared to omeprazole‐based therapy, but only for homologous extensive metabolizers of CYP2C19.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15691303</pmid><doi>10.1111/j.1365-2036.2005.02281.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2005-02, Vol.21 (3), p.283-288 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67406949 |
| source | Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Amoxicillin - administration & dosage Amoxicillin - therapeutic use Anti-Bacterial Agents - therapeutic use Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - therapeutic use Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Biological and medical sciences Chi-Square Distribution Clarithromycin - administration & dosage Clarithromycin - therapeutic use Cytochrome P-450 CYP2C19 Digestive system Drug Administration Schedule Drug Therapy, Combination Esomeprazole Female Follow-Up Studies Gastric Mucosa - enzymology Gastroenterology. Liver. Pancreas. Abdomen Genotype Helicobacter Infections - drug therapy Helicobacter Infections - enzymology Helicobacter pylori Humans Male Medical sciences Mixed Function Oxygenases - genetics Mixed Function Oxygenases - metabolism Omeprazole - administration & dosage Omeprazole - therapeutic use Pharmacology. Drug treatments Risk |
| title | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A13%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Esomeprazole%2040%E2%80%83mg%20twice%20daily%20in%20triple%20therapy%20and%20the%20efficacy%20of%20Helicobacter%20pylori%20eradication%20related%20to%20CYP2C19%20metabolism&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Sheu,%20B.%E2%80%90S.&rft.date=2005-02&rft.volume=21&rft.issue=3&rft.spage=283&rft.epage=288&rft.pages=283-288&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2005.02281.x&rft_dat=%3Cproquest_cross%3E67406949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67406949&rft_id=info:pmid/15691303&rfr_iscdi=true |